Diabetes Care, Vol 17, Issue 4 263-266, Copyright © 1994 by American Diabetes Association

ARTICLES

Increased urinary endothelin-1-like immunoreactivity excretion in NIDDM patients with albuminuria

YJ Lee, SJ Shin and JH Tsai
Department of Internal Medicine, Kaohsiung Medical College, Taiwan, Republic of China.

OBJECTIVE--To determine the urinary endothelin-1-like immunoreactivity (ET-1-LI) in non-insulin-dependent diabetes mellitus (NIDDM) patients and to investigate whether urinary ET-1-LI excretion is elevated in patients with albuminuria. RESEARCH DESIGN AND METHODS--Urinary ET-1-LI substance was determined by radioimmunoassay in 45 normoalbuminuric and 28 albuminuric NIDDM patients. RESULTS--The mean amounts of 24-h ET-1-LI excretion in NIDDM patients with normoalbuminuria and albuminuria were 154.9 +/- 13.5 and 174.4 +/- 12.9 ng/day, respectively. The latter was significantly higher than that of the 40 normal control subjects (111.8 +/- 7.9 ng/day, P < 0.01). CONCLUSIONS--The increase in urinary ET-1-LI substance excretion in patients with albuminuria suggests that ET-1 may be a pathogenetic factor in diabetic nephropathy.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				M. Iglarz, C. Binkert, K. Morrison, W. Fischli, J. Gatfield, A. Treiber, T. Weller, M. H. Bolli, C. Boss, S. Buchmann, et al. Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist J. Pharmacol. Exp. Ther., December 1, 2008; 327(3): 736 - 745. [Abstract] [Full Text] [PDF]

				T. Slowinski, P. Kalk, M. Christian, F. Schmager, K. Relle, M. Godes, H. Funke-Kaiser, H.-H. Neumayer, C. Bauer, F. Theuring, et al. Cell-type specific interaction of endothelin and the nitric oxide system: pattern of prepro-ET-1 expression in kidneys of L-NAME treated prepro-ET-1 promoter-lacZ-transgenic mice J. Physiol., June 15, 2007; 581(3): 1173 - 1181. [Abstract] [Full Text] [PDF]

				I. LEHRKE, R. WALDHERR, E. RITZ, and J. WAGNER Renal Endothelin-1 and Endothelin Receptor Type B Expression in Glomerular Diseases with Proteinuria J. Am. Soc. Nephrol., November 1, 2001; 12(11): 2321 - 2329. [Abstract] [Full Text] [PDF]

				T.-J. Hsieh, S.-R. Lin, Y.-J. Lee, S.-J. Shin, Y.-H. Lai, C.-H. Hsu, and J.-H. Tsai Increased renal medullary endothelin-1 synthesis in prehypertensive DOCA- and salt-treated rats Am J Physiol Renal Physiol, July 1, 2000; 279(1): F112 - F121. [Abstract] [Full Text] [PDF]

				T. J Rabelink, E. S.G Stroes, K.P. Bouter, and P. Morrison Endothelin blockers and renal protection: a new strategy to prevent end-organ damage in cardiovascular disease? Cardiovasc Res, September 1, 1998; 39(3): 543 - 549. [Full Text] [PDF]